MedPath

Patient and Physician Knowledge of Key Safety Messages

Completed
Conditions
Anticoagulation
Interventions
Behavioral: Rivaroxaban (Xarelto, BAY59-7939)
Registration Number
NCT01907048
Lead Sponsor
Bayer
Brief Summary

This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2227
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Group 1Rivaroxaban (Xarelto, BAY59-7939)Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
Group 2Rivaroxaban (Xarelto, BAY59-7939)Survey to measure patient awareness and understanding of the key messages in the patient card.
Primary Outcome Measures
NameTimeMethod
Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaireUp to 18 months
Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaireUp to 18 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath